Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy - PubMed (original) (raw)
Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy
C F Nathan et al. N Engl J Med. 1986.
Abstract
Evidence that interferon-gamma may be a physiologic macrophage-activating factor, and that macrophage activation may be defective in lepromatous leprosy, led us to test the effects of intradermal injection of low doses of recombinant interferon-gamma in six patients with this disease. Interferon-gamma, 1 or 10 micrograms, was administered daily by jet gun for three days into a single cutaneous lesion. A biopsy specimen was taken from the injection site on the sixth study day and compared with specimens obtained previously from a site where no injection had been made or where excipient alone had been injected in the same way as the interferon. Interferon-gamma elicited local effects similar to certain features of delayed-type hypersensitivity reactions or tuberculoid leprosy, including induration, T-cell and monocyte infiltration, keratinocyte proliferation, diminution of epidermal Langerhans cells, and dermal and epidermal cell HLA-DR (Ia) antigen expression. At some of the sites of interferon-gamma injection, there was also an apparent decrease in acid-fast bacilli. Before treatment, monocytes from patients with lepromatous leprosy released 48 percent as much hydrogen peroxide as did monocytes from controls in response to phorbol myristate acetate, and 36 percent as much as those from controls in response to Mycobacterium leprae. When recombinant interferon-gamma was injected, these responses became normal. No toxic effects were observed. These observations suggest that interferon-gamma can mediate certain manifestations of delayed-type hypersensitivity or cell-mediated immunity in vivo, and that recombinant interferon-gamma should be tested for possible therapeutic effects in certain nonviral infectious diseases.
Similar articles
- Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients.
Kaplan G, Nusrat A, Sarno EN, Job CK, McElrath J, Porto JA, Nathan CF, Cohn ZA. Kaplan G, et al. Am J Pathol. 1987 Aug;128(2):345-53. Am J Pathol. 1987. PMID: 3113256 Free PMC article. - Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae.
Kaplan G, Mathur NK, Job CK, Nath I, Cohn ZA. Kaplan G, et al. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8073-7. doi: 10.1073/pnas.86.20.8073. Proc Natl Acad Sci U S A. 1989. PMID: 2510159 Free PMC article. - Effect of cutaneous cell-mediated immune response to rIFN gamma on Mycobacterium leprae viability in the lesions of lepromatous leprosy.
Damasco MH, Sarno EN, Lobão AS, Alvarenga FB, Porto JA, Rosankaimer F, Kaplan G. Damasco MH, et al. Braz J Med Biol Res. 1992;25(5):457-65. Braz J Med Biol Res. 1992. PMID: 1342221 - Recent advances in cytokine therapy in leprosy.
Kaplan G. Kaplan G. J Infect Dis. 1993 Mar;167 Suppl 1:S18-22. doi: 10.1093/infdis/167.supplement_1.s18. J Infect Dis. 1993. PMID: 8433015 Review. - The immunobiology of leprosy.
Kaplan G, Cohn ZA. Kaplan G, et al. Int Rev Exp Pathol. 1986;28:45-78. Int Rev Exp Pathol. 1986. PMID: 3516911 Review.
Cited by
- New Approaches to Tackling Intractable Issues in Infectious Disease.
Barrow P. Barrow P. Microorganisms. 2024 Feb 20;12(3):421. doi: 10.3390/microorganisms12030421. Microorganisms. 2024. PMID: 38543472 Free PMC article. Review. - Mycobacterium tuberculosis as teacher.
Nathan C. Nathan C. Nat Microbiol. 2023 Sep;8(9):1606-1608. doi: 10.1038/s41564-023-01454-3. Nat Microbiol. 2023. PMID: 37587200 No abstract available. - Revisiting Persistent Salmonella Infection and the Carrier State: What Do We Know?
Foster N, Tang Y, Berchieri A, Geng S, Jiao X, Barrow P. Foster N, et al. Pathogens. 2021 Oct 9;10(10):1299. doi: 10.3390/pathogens10101299. Pathogens. 2021. PMID: 34684248 Free PMC article. Review. - Comment on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections".
Puel A, Casanova JL. Puel A, et al. Science. 2021 Sep 17;373(6561):eabi5459. doi: 10.1126/science.abi5459. Epub 2021 Sep 16. Science. 2021. PMID: 34529464 Free PMC article. - Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.
Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, Temesgen Z. Pennington KM, et al. J Clin Tuberc Other Mycobact Dis. 2021 May 8;24:100244. doi: 10.1016/j.jctube.2021.100244. eCollection 2021 Aug. J Clin Tuberc Other Mycobact Dis. 2021. PMID: 34036184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials